Nexus Surgical & Medicare Intrinsic Value
Nexus Surgical & Medicare intrinsic value. Nexus Surgical & Medicare (NEXUSSURGL) median intrinsic value is ₹15.00 from 8 valuation models (range ₹7–₹27), vs current price ₹32.95 — -54.5% downside (Trading Above Calculated Value), margin of safety -100.0%. Read NEXUSSURGL dividend yield for the complete payout history and dividend yield track record.
NEXUSSURGL Valuation Methods Summary — DCF, Graham Number & P/E
Nexus Surgical & Medicare intrinsic value across 8 models vs current price ₹32.95 — upside/downside and value range per method. For current market price and key ratios, visit Nexus Surgical & Medicare stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹16.80 | ₹13.44 - ₹20.16 | -49.0% | EPS: ₹1.40, Sector P/E: 12x |
| Book Value Method | asset | ₹6.59 | ₹5.93 - ₹7.25 | -80.0% | Book Value/Share: ₹3.33, P/B: 0.8x |
| Revenue Multiple Method | revenue | ₹15.00 | ₹13.50 - ₹16.50 | -54.5% | Revenue/Share: ₹15.00, P/S: 1.0x |
| EBITDA Multiple Method | earnings | ₹13.18 | ₹11.86 - ₹14.50 | -60.0% | EBITDA: ₹1.00Cr, EV/EBITDA: 5x |
| PEG Ratio Method | growth | ₹22.40 | ₹20.16 - ₹24.64 | -32.0% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹12.04 | ₹10.84 - ₹13.24 | -63.5% | Revenue Growth: 15.0%, Adj P/E: 8.6x |
| ROE Based Valuation | profitability | ₹26.67 | ₹24.00 - ₹29.34 | -19.1% | ROE: 50.0%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹9.88 | ₹8.89 - ₹10.87 | -70.0% | EPS: ₹1.40, BVPS: ₹3.33 |
NEXUSSURGL Intrinsic Value vs Market Price — All Valuation Models
Nexus Surgical & Medicare fair value range ₹7–₹27 vs current market price ₹32.95 across 8 valuation models. Compare with NEXUSSURGL fundamental valuation to assess whether the stock is under or overvalued.
NEXUSSURGL Intrinsic Value Analysis — Undervalued or Overvalued?
Nexus Surgical & Medicare median intrinsic value ₹15.00, current price ₹32.95 — Trading Above Calculated Value by 54.5%, margin of safety -100.0%.
What is the intrinsic value of NEXUSSURGL?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Nexus Surgical & Medicare (NEXUSSURGL) is ₹15.00 (median value). With the current market price of ₹32.95, this represents a -54.5% variance from our estimated fair value.
The valuation range spans from ₹6.59 to ₹26.67, indicating ₹6.59 - ₹26.67.
Is NEXUSSURGL undervalued or overvalued?
Based on our multi-method analysis, Nexus Surgical & Medicare (NEXUSSURGL) appears to be trading above calculated value by approximately 54.5%.
NEXUSSURGL Financial Health — Key Ratios vs Industry Benchmarks
Nexus Surgical & Medicare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 50.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 2.25x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
NEXUSSURGL Cash Flow Quality — Operating & Free Cash Flow
Nexus Surgical & Medicare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |